Tyler J. Alban

Tyler J. Alban

Auto-generated profile, based on publicly available information

Tyler J. Alban

Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 November 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
TATyler J. Alban
Tyler J. Alban
AAAlvaro G. Alvarado
Alvaro G. Alvarado
MSMia D. Sorensen
Mia D. Sorensen
DBDefne Bayik
Defne Bayik
JVJosephine Volovetz
Josephine Volovetz
JLJustin Lathia
Justin Lathia
Glioblastoma (GBM) remains uniformly lethal, and despite a large accumulation of immune cells in the microenvironment, there is limited antitumor immune response. To overcome these challenges, a comprehensive understanding of GBM systemic immune response during disease progression is required. Here, we integrated multiparameter flow cytometry and mass cytometry TOF (CyTOF) analysis of patient blood to determine changes in the immune system among tumor types and over disease progression. Utilizing flow cytometry analysis in a cohort of 259 patients ranging from benign to malignant primary and metastatic brain tumors, we found that GBM patients had a significant elevation in myeloid-derived suppressor cells (MDSCs) in peripheral blood but not immunosuppressive Tregs. In GBM patient tissue, we found that increased MDSC levels in recurrent GBM portended poor prognosis. CyTOF analysis of peripheral blood from newly diagnosed GBM patients revealed that reduced MDSCs over time were accompanied by a concomitant increase in DCs. GBM patients with extended survival also had reduced MDSCs, similar to the levels of low-grade glioma (LGG) patients. Our findings provide a rationale for developing strategies to target MDSCs, which are elevated in GBM patients and predict poor prognosis.

1 April 2017 in Cell Stem Cell
Verified
Journal Article
Closed access
AAAlvaro G. Alvarado
Alvaro G. Alvarado
PTPraveena S. Thiagarajan
Praveena S. Thiagarajan
EMErin Mulkearns-Hubert
Erin Mulkearns-Hubert
DSDaniel J. Silver
Daniel J. Silver
JHJames S. Hale
James S. Hale
JLJustin Lathia
Justin Lathia

14 November 2019 in JCI Insight
Verified
Journal Article
Closed access
PDF file
DPDavid Peereboom
David Peereboom
TATyler J. Alban
Tyler J. Alban
MGMatthew M. Grabowski
Matthew M. Grabowski
AAAlvaro G. Alvarado
Alvaro G. Alvarado
BOBalint Otvos
Balint Otvos
JLJustin Lathia
Justin Lathia
BACKGROUND: Myeloid-derived suppressor cells (MDSCs) are elevated in the circulation of patients with glioblastoma (GBM), present in tumor tissue, and associated with poor prognosis. While low-dose chemotherapy reduces MDSCs in preclinical models, the use of this strategy to reduce MDSCs in GBM patients has yet to be evaluated. METHODS: A phase 0/I dose-escalation clinical trial was conducted in patients with recurrent GBM treated 5–7 days before surgery with low-dose chemotherapy via capecitabine, followed by concomitant low-dose capecitabine and bevacizumab. Clinical outcomes, including progression-free and overall survival, were measured, along with safety and toxicity profiles. Over the treatment time course, circulating MDSC levels were measured by multiparameter flow cytometry, and tumor tissue immune profiles were assessed via time-of-flight mass cytometry. RESULTS: Eleven patients total were enrolled across escalating dose cohorts of 150, 300, and 450 mg bid. No serious adverse events related to the drug combination were observed. Compared with pretreatment baseline, circulating MDSCs were found to be higher after surgery in the 150-mg treatment arm and lower in the 300-mg and 450-mg treatment arms. Increased cytotoxic immune infiltration was observed after low-dose capecitabine compared with untreated GBM patients in the 300-mg and 450-mg treatment arms. CONCLUSIONS: Low-dose, metronomic capecitabine in combination with bevacizumab was well tolerated in GBM patients and was associated with a reduction in circulating MDSC levels and an increase in cytotoxic immune infiltration into the tumor microenvironment. TRIAL REGISTRATION: ClinicalTrials.gov NCT02669173. FUNDING: This research was funded by the Cleveland Clinic, Case Comprehensive Cancer Center, the Musella Foundation, B*CURED, the NIH, the National Cancer Institute, the Sontag Foundation, Blast GBM, the James B. Pendleton Charitable Trust, and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation. Capecitabine was provided in kind by Mylan Pharmaceuticals.

1 April 2021 in Med
Verified
Journal Article
Closed access
JRJoanna Roopkumar
Joanna Roopkumar
SSShadi Swaidani
Shadi Swaidani
AKAnn S. Kim
Ann S. Kim
BTBicky Thapa
Bicky Thapa
LGLorenzo Gervaso
Lorenzo Gervaso
AKAlok A. Khorana
Alok A. Khorana

8 February 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
PTPraveena S. Thiagarajan
Praveena S. Thiagarajan
MSMaksim Sinyuk
Maksim Sinyuk
STSoumya M. Turaga
Soumya M. Turaga
EMErin Mulkearns-Hubert
Erin Mulkearns-Hubert
JHJames S. Hale
James S. Hale
JLJustin Lathia
Justin Lathia
Tumors adapt their phenotypes during growth and in response to therapies through dynamic changes in cellular processes. Connexin proteins enable such dynamic changes during development, and their dysregulation leads to disease states. The gap junction communication channels formed by connexins have been reported to exhibit tumor-suppressive functions, including in triple-negative breast cancer (TNBC). However, we find that connexin 26 (Cx26) is elevated in self-renewing cancer stem cells (CSCs) and is necessary and sufficient for their maintenance. Cx26 promotes CSC self-renewal by forming a signaling complex with the pluripotency transcription factor NANOG and focal adhesion kinase (FAK), resulting in NANOG stabilization and FAK activation. This FAK/NANOG-containing complex is not formed in mammary epithelial or luminal breast cancer cells. These findings challenge the paradigm that connexins are tumor suppressors in TNBC and reveal a unique function for Cx26 in regulating the core self-renewal signaling that controls CSC maintenance.

8 December 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KAKeiichi Asano
Keiichi Asano
CNCourtney M. Nelson
Courtney M. Nelson
SNSumeda Nandadasa
Sumeda Nandadasa
NANoriko Aramaki-Hattori
Noriko Aramaki-Hattori
DLDaniel J. Lindner
Daniel J. Lindner
SHSatoshi Hirohata
Satoshi Hirohata
The proteoglycan versican is implicated in growth and metastases of several cancers. Here we investigated a potential contribution of stromal versican to tumor growth and angiogenesis. We initially determined versican expression by several cancer cell lines. Among these, MDA-MB231 and B16F10 had none to minimal expression in contrast to Lewis lung carcinoma (LLC). Notably, tumors arising from these cell lines had higher versican levels than the cell lines themselves suggesting a contribution from the host-derived tumor stroma. In LLC-derived tumors, both the tumor and stroma expressed versican at high levels. Thus, tumor stroma can make a significant contribution to tumor versican content. Versican localized preferentially to the vicinity of tumor vasculature and macrophages in the tumor. However, an ADAMTS protease-generated versican fragment uniquely localized to vascular endothelium. To specifically determine the impact of host/stroma-derived versican we therefore compared growth of tumors from B16F10 cells, which produced littleversican, inVcanhdf/+mice and wild-type littermates. Tumors inVcanhdf/+mice had reduced growth with a lower capillary density and accumulation of capillaries at the tumor periphery. These findings illustrate the variability of tumor cell line expression of versican, and demonstrate that versican is consistently contributed by the stromal tissue, where it contributes to tumor angiogenesis.